NCT05698420

Brief Summary

In this study, the investigators aimed to observe the effects of medium cut-off dialysis filters and high-flux dialysis filters on malnutrition inflammation score, uremic itching, restless leg syndrome, anemia, and ESA treatment, which are prominent complications in hemodialysis, and routine follow-up parameters.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2020

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

January 5, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

January 26, 2023

Completed
Last Updated

May 14, 2024

Status Verified

May 1, 2024

Enrollment Period

7 months

First QC Date

January 5, 2023

Last Update Submit

May 12, 2024

Conditions

Outcome Measures

Primary Outcomes (38)

  • Malnutrition-inflammation score (MIS)

    At the start of the study, the malnutrition-inflammation score will be recorded. This score ranges from 0 to 30, with higher scores indicating worse outcomes.

    Prior to randomization, at the start of the study.

  • Malnutrition-inflammation score (MIS)

    The malnutrition-inflammation score will be recorded at the conclusion of the study. This score ranges from 0 to 30, with higher scores indicating worse outcomes.

    At the end of the 6th month after randomization.

  • Depressive disorder

    At the start of the study, the Beck's depression scale will be recorded. This score ranges from 0 to 63, with higher scores indicating worse depression.

    Prior to randomization, at the start of the study.

  • Depressive disorder

    At the conclusion of the study, the Beck's depression scale will be recorded. This score ranges from 0 to 63, with higher scores indicating worse depression.

    At the end of the 6th month after randomization.

  • Uremic pruritus

    At the start of the study, the visual analog scale for pruritus will be recorded. This score ranges from 0 to 10, with higher scores indicating worse itching.

    Prior to randomization, at the start of the study.

  • Uremic pruritus

    At the conclusion of the study, the visual analog scale for pruritus will be recorded. This score ranges from 0 to 10, with higher scores indicating worse itching.

    At the end of the 6th month after randomization.

  • Restless leg syndrome

    At the start of the study, the Restless Leg Syndrome screening questionnaire will be administered. This score ranges from 0 to 40, with higher scores indicating worse symptoms.

    Prior to randomization, at the start of the study.

  • Restless leg syndrome

    At the conclusion of the study, the Restless Leg Syndrome screening questionnaire will be administered. This score ranges from 0 to 40, with higher scores indicating worse symptoms.

    At the end of the 6th month after randomization.

  • Appetite

    At the start of the study, the visual analog scale of appetite will be recorded. This score ranges from 0 to 5, with higher scores indicating better appetite.

    Prior to randomization, at the start of the study.

  • Appetite

    At the conclusion of the study, the visual analog scale of appetite will be recorded. This score ranges from 0 to 5, with higher scores indicating better appetite.

    At the end of the 6th month after randomization.

  • Hemoglobin

    Hemoglobin levels will be measured on a monthly basis.

    March 2020

  • Hemoglobin

    Hemoglobin levels will be measured on a monthly basis.

    April 2020

  • Hemoglobin

    Hemoglobin levels will be measured on a monthly basis.

    May 2020

  • Hemoglobin

    Hemoglobin levels will be measured on a monthly basis.

    June 2020

  • Hemoglobin

    Hemoglobin levels will be measured on a monthly basis.

    July 2020

  • Hemoglobin

    Hemoglobin levels will be measured on a monthly basis.

    August 2020

  • Hemoglobin

    Hemoglobin levels will be measured on a monthly basis.

    September 2020

  • Erythropoietin Doses

    Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.

    March 2020

  • Erythropoietin Doses

    Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.

    April 2020

  • Erythropoietin Doses

    Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.

    May 2020

  • Erythropoietin Doses

    Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.

    June 2020

  • Erythropoietin Doses

    Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.

    July 2020

  • Erythropoietin Doses

    Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.

    August 2020

  • Erythropoietin Doses

    Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.

    September 2020

  • Phosphorus levels control

    Serum phosphorus levels will be tested on a monthly basis.

    March 2020

  • Phosphorus levels control

    Serum phosphorus levels will be tested on a monthly basis.

    April 2020

  • Phosphorus levels control

    Serum phosphorus levels will be tested on a monthly basis.

    May 2020

  • Phosphorus levels control

    Serum phosphorus levels will be tested on a monthly basis.

    June 2020

  • Phosphorus levels control

    Serum phosphorus levels will be tested on a monthly basis.

    July 2020

  • Phosphorus levels control

    Serum phosphorus levels will be tested on a monthly basis.

    August 2020

  • Phosphorus levels control

    Serum phosphorus levels will be tested on a monthly basis.

    September 2020

  • Parathyroid hormone levels control

    Serum parathyroid hormone levels will be tested on a monthly basis.

    March 2020

  • Parathyroid hormone levels control

    Serum parathyroid hormone levels will be tested on a monthly basis.

    April 2020

  • Parathyroid hormone levels control

    Serum parathyroid hormone levels will be tested on a monthly basis.

    May 2020

  • Parathyroid hormone levels control

    Serum parathyroid hormone levels will be tested on a monthly basis.

    June 2020

  • Parathyroid hormone levels control

    Serum parathyroid hormone levels will be tested on a monthly basis.

    July 2020

  • Parathyroid hormone levels control

    Serum parathyroid hormone levels will be tested on a monthly basis.

    August 2020

  • Parathyroid hormone levels control

    Serum parathyroid hormone levels will be tested on a monthly basis.

    September 2020

Study Arms (2)

The Theranova 400 group, also known as the MCO group.

Patients undergoing maintenance hemodialysis will receive dialysis treatment using the Theranova 400 device.

Device: Dialysis using the Theranova-400 device.

The FX80 group, also known as the high-flux group.

Patients undergoing maintenance hemodialysis will receive dialysis treatment using the FX80 device.

Device: Dialysis using the FX80 device.

Interventions

Patients receive hemodialysis treatment using the Theranova-400 dialyzer.

The Theranova 400 group, also known as the MCO group.

Patients receive hemodialysis treatment using the FX80 dialyzer.

The FX80 group, also known as the high-flux group.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Prevalent patients who are receiving hemodialysis treatment three times a week and are otherwise in stable condition.

You may qualify if:

  • Chronic hemodialysis patients
  • Patients continuing the hemodialysis program for at least 3 months
  • Patients over 18 years of age

You may not qualify if:

  • Patients with advanced heart failure, malignancy, terminal illness
  • Patients with active infectious disease
  • Acute hemodialysis patients
  • Patients vascular access dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mehmet Akif Inan Training and Research Hospital

Sanliurfa, Karaköprü, 63000, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum and plasma extracts from venous blood samples were stored at -80C of the hospital.

MeSH Terms

Conditions

Restless Legs SyndromeDepressive Disorder

Condition Hierarchy (Ancestors)

Nervous System DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersParasomniasMental DisordersMood Disorders

Study Officials

  • Tuncay Sahutoglu, M.D.

    Mehmet Akif Inan Training and Research Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 5, 2023

First Posted

January 26, 2023

Study Start

March 1, 2020

Primary Completion

September 30, 2020

Study Completion

October 31, 2020

Last Updated

May 14, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations